Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021
Abstract Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients with different cancers has focused attention on t...
Main Authors: | Paolo A. Ascierto, Antonio Avallone, Nina Bhardwaj, Carlo Bifulco, Sergio Bracarda, Joshua D. Brody, Luigi Buonaguro, Sandra Demaria, Leisha A. Emens, Robert L. Ferris, Jérôme Galon, Samir N. Khleif, Christopher A. Klebanoff, Tamara Laskowski, Ignacio Melero, Chrystal M. Paulos, Sandro Pignata, Marco Ruella, Inge Marie Svane, Janis M. Taube, Bernard A. Fox, Patrick Hwu, Igor Puzanov |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-06-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-022-03471-y |
Similar Items
-
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
by: Paolo A. Ascierto, et al.
Published: (2018-07-01) -
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)
by: Paolo A. Ascierto, et al.
Published: (2019-11-01) -
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
by: Paolo A. Ascierto, et al.
Published: (2023-07-01) -
It’s TIME for a biomarker-driven approach to cancer immunotherapy
by: Leisha A Emens
Published: (2016-06-01) -
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
by: Paolo A. Ascierto, et al.
Published: (2023-04-01)